oncotomskСибирский онкологический журналSiberian journal of oncology1814-48612312-3168Tomsk National Research Medical Сепtеr of the Russian Academy of Sciencesoncotomsk-203Research ArticleОПЫТ РАБОТЫ ОНКОЛОГИЧЕСКИХ УЧРЕЖДЕНИЙONCOLOGY PRACTICEОСОБЕННОСТИ МЕТОДОВ ДИАГНОСТИКИ МЕТАСТАЗОВ В ЛЕГКИЕ ДИФФЕРЕНЦИРОВАННОГО РАКА ЩИТОВИДНОЙ ЖЕЛЕЗЫDIAGNOSTIC IMAGING MODALITIES FOR DETECTION OF LUNG METASTASES IN PATIENTS WITH DIFFRENTIATED THYROID CANCERГелиашвилиТ. М.GeliashviliТ. М.

Гелиашвили Тамара Мамуковна, врач-радиолог, радиотерапевтическое отделения системной терапии.

Geliashvili Tamara Mamukovna, MD, radiologist, Radiation Therapy Department. 

E-mail: geliashvili_tata@mail.ru.

geliashvili_tata@mail.ruВаженинА. В.VazheninA. V.

Важенин Андрей Владимирович, доктор медицинских наук, профессор, член-корреспондент Российской академии наук, заслуженный врач Российской Федерации; заведующий кафедрой онкологии, лучевой диагностики и лучевой терапии, Южно- Уральский государственный медицинский университет; главный врач ГБУЗ «Челябинский областной клинический онкологический диспансер».

Vazhenin Andrey Vladimirovich, MD, Professor, Corresponding Member of RAS, Honored physician of RF, Head of Department of Oncology, Radiation Therapy and Diagnostic Imaging, South-Ural State Medical University, Head Physician of Chelyabinsk Regional Clinical Oncology Center.

E-mail: roc_chel@mail.ru. SPIN-code: 1350-9411.

roc_chel@mail.ruВасильеваЕ. Б.VasilyevaЕ. B.

Васильева Екатерина Борисовна, кандидат медицинских наук, заведующая радиотерапевтическим отделением системной терапии. 

E-mail: v_kat@rambler.ru.

Vasilyeva Ekaterina Borisovna, MD, PhD, Head of Radiation Therapy Department.

v_kat@rambler.ruАфанасьеваН. Г.AfanasyevaN. G.

Афанасьева Надежда Геннадьевна, кандидат медицинских наук, заведующая центром позитронной эмиссионной томографии. 

E-mail: afanas_ng@mail.ru.

Afanasyeva Nadezhda Gennadievna, MD, PhD, Head ofPositronEmissionTomographyCenter.

afanas_ng@mail.ruЧелябинский областной клинический онкологический диспансерРоссияChelyabinsk Regional Oncology Center, ChelyabinskRussian Federation201520022016065760Copyright © Гелиашвили Т.М., Важенин А.В., Васильева Е.Б., Афанасьева Н.Г., 20162016Гелиашвили Т.М., Важенин А.В., Васильева Е.Б., Афанасьева Н.Г.Geliashvili Т.М., Vazhenin A.V., Vasilyeva Е.B., Afanasyeva N.G.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.siboncoj.ru/jour/article/view/203

Целью исследования явилась сравнительная оценка эффективности различных методов диагностики в выявлении метастазов в легкие дифференцированного рака щитовидной железы (ДРЩЖ). Проведен ретроспективный анализ результатов обследования 36 больных. Установлено, что наибольшей чувствительностью обладают МСКТ органов грудной клетки (95,5 %), ПЭТ/КТ с 18-ФДГ (100 %, за счет наличия режима КТ) и СВТ с 131I (66,7 %).

The aim of the study was to comparatively assess the efficacy of various diagnostic imaging modalities in detection of lung metastases of differentiated thyroid cancer. A retrospective analysis of the results of examination of 36 patients was carried out. Positron emission tomography/computed tomography (PET/ CT) with [F-18] fluorodeoxyglucose (FDG) was found to have the highest sensitivity for detection of lung metastases of differentiated thyroid cancer (100 %) followed by CT of the chest (95.5 %) and whole body scintigraphy (WBS) with 131I (66.7 %).

дифференцированный рак щитовидной железыметастазы в легкиеПЭТ/КТ с 18-ФДГМСКТ органов грудной клеткисцинтиграфия всего тела с 131Idifferentiated thyroid cancerlung metastases18F-FDG PET-CTCT of the chestwhole body scintigraphy with 131IReferencesКаприн А.Д., Старинский В.В., Петрова Г.В. Злокачественные новообразования в России в 2012 г. (заболеваемость и смертность). М., 2014. 250 с.Kaprin A.D., Starinskij V.V., Petrova G.V. Cancer incidence in Russia in 2012 (morbidity and mortality). Moscow, 2014. 250 p. [in Russian]Casara D., Rubello D., Saladini G., Masarotto G., Favero A., Girelli M.E., Busnardo B. Different features of pulmonary metastases in differentiated thyroid cancer: natural history and multivariate analysis of prognostic variables // J. Nucl. Med. 1993. Vol. 34 (11). P. 1626–1631.Casara D., Rubello D., Saladini G., Masarotto G., Favero A., Girelli M.E., Busnardo B. Different features of pulmonary metastases in differentiated thyroid cancer: natural history and multivariate analysis of prognostic variables // J. Nucl. Med. 1993. Vol. 34 (11). P. 1626–1631.Davies L., Welch H.G. Increasing Incidence of Thyroid Cancer in the United States, 1973-2002 // JAMA. 2006. Vol. 295 (18). P. 2164–2167.Davies L., Welch H.G. Increasing Incidence of Thyroid Cancer in the United States, 1973-2002 // JAMA. 2006. Vol. 295 (18). P. 2164–2167.Dinneen S.F., Valimaki M.J., Bergstralh E.J., Goellner J.R., Gorman C.A., Hay I.D. Distant metastases in papillary thyroid carcinoma: 100 cases observed at one institution during 5 decades // J. Clin. Endocrinol. Metabol. 1995. Vol. 80 (7). P. 2041–2045.Dinneen S.F., Valimaki M.J., Bergstralh E.J., Goellner J.R., Gorman C.A., Hay I.D. Distant metastases in papillary thyroid carcinoma: 100 cases observed at one institution during 5 decades // J. Clin. Endocrinol. Metabol. 1995. Vol. 80 (7). P. 2041–2045.Durante C., Haddy N., Baudin E., Leboulleux S., Hartl D., Travagli J.P., Caillou B., Ricard M., Lumbroso J.D., De Vathaire F., Schlumberger M. Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: Benefits and limits of radioiodine therapy // J. Clin. Endocrinol. Metabol. 2006. Vol. 91 (8). P. 2892–2289.Durante C., Haddy N., Baudin E., Leboulleux S., Hartl D., Travagli J.P., Caillou B., Ricard M., Lumbroso J.D., De Vathaire F., Schlumberger M. Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: Benefits and limits of radioiodine therapy // J. Clin. Endocrinol. Metabol. 2006. Vol. 91 (8). P. 2892–2289.Eustatia-Rutten C.F., Corssmit E.P., Biermasz N.R., Pereira A.M., Romijn J.A., Smit J.W. Survival and death causes in differentiated thyroid carcinoma // J. Clin. Endocrinol. Metabol. 2006. Vol. 91 (1). P. 313–319.Eustatia-Rutten C.F., Corssmit E.P., Biermasz N.R., Pereira A.M., Romijn J.A., Smit J.W. Survival and death causes in differentiated thyroid carcinoma // J. Clin. Endocrinol. Metabol. 2006. Vol. 91 (1). P. 313–319.Hooft L., Hoekstra O.S., Devillé W., Lips P., Teule G.J., Boers M., van Tulder M.W. Diagnostic accuracy of 18F-fluorodeoxyglucose positron emission tomography in the follow-up of papillary or follicular thyroid cancer // J. Clin. Endocrinol. Metabol. 2001. Vol. 86 (8). P. 3779–3786.Hooft L., Hoekstra O.S., Devillé W., Lips P., Teule G.J., Boers M., van Tulder M.W. Diagnostic accuracy of 18F-fluorodeoxyglucose positron emission tomography in the follow-up of papillary or follicular thyroid cancer // J. Clin. Endocrinol. Metabol. 2001. Vol. 86 (8). P. 3779–3786.Khan N., Oriuchi N., Higuchi T., Zhang H., Endo K. PET in the follow-up of differentiated thyroid cancer // Br. J. Radiol. 2003. Vol. 76 (10). P. 690–695.Khan N., Oriuchi N., Higuchi T., Zhang H., Endo K. PET in the follow-up of differentiated thyroid cancer // Br. J. Radiol. 2003. Vol. 76 (10). P. 690–695.O’Neill C.J., Oucharek J., Learoyd D., Sidhu S.B. Standard and emerging therapies for metastatic differentiated thyroid cancer // Oncologist. 2010. Vol. 15 (2). P. 146–156. doi: 10.1634/theoncologist.2009- 0190.O’Neill C.J., Oucharek J., Learoyd D., Sidhu S.B. Standard and emerging therapies for metastatic differentiated thyroid cancer // Oncologist. 2010. Vol. 15 (2). P. 146–156. doi: 10.1634/theoncologist.2009- 0190.Schlumberger M.J. Diagnostic follow-up of well-differentiated thyroid carcinoma: Historical perspective and current status // J. Endocrinol. Investig. 1999. Vol. 22 (11). Suppl. P. 3–7.Schlumberger M.J. Diagnostic follow-up of well-differentiated thyroid carcinoma: Historical perspective and current status // J. Endocrinol. Investig. 1999. Vol. 22 (11). Suppl. P. 3–7.Schlumberger M.J., Arcangioli O., Piekarski J.D., Tubiana M., Parmentier C. Detection and treatment of lung metastases of differentiated thyroid carcinoma in patients with normal chest X-rays // J. Nucl. Med. 1988. Vol. 29 (11). P. 1790–1794.Schlumberger M.J., Arcangioli O., Piekarski J.D., Tubiana M., Parmentier C. Detection and treatment of lung metastases of differentiated thyroid carcinoma in patients with normal chest X-rays // J. Nucl. Med. 1988. Vol. 29 (11). P. 1790–1794.Sherman S.I. Thyroid carcinoma // Lancet. 2003. Vol. 361 (9356). P. 501–511.Sherman S.I. Thyroid carcinoma // Lancet. 2003. Vol. 361 (9356). P. 501–511.Sipos J.A., Mazzaferri E.L. Thyroid Cancer Epidemiology and Prognostic Variables // Clin. Oncol. (R. Coll. Radiol.). 2010. Vol. 22 (6). P. 395–404. doi: 10.1016/j.clon.2010.05.004.Sipos J.A., Mazzaferri E.L. Thyroid Cancer Epidemiology and Prognostic Variables // Clin. Oncol. (R. Coll. Radiol.). 2010. Vol. 22 (6). P. 395–404. doi: 10.1016/j.clon.2010.05.004.Sisson J.C., Ackerman R.J., Meyer M.A., Wahl R.L. Uptake of 18- fluoro-2-deoxy-D-glucose by thyroid cancer: implications for diagnosis and therapy // J. Clin. Endocrinol. Metabol. 1993. Vol. 77 (4). P. 1090–1094.Sisson J.C., Ackerman R.J., Meyer M.A., Wahl R.L. Uptake of 18- fluoro-2-deoxy-D-glucose by thyroid cancer: implications for diagnosis and therapy // J. Clin. Endocrinol. Metabol. 1993. Vol. 77 (4). P. 1090–1094.Wang H., Fu H.L., Li J.N., Zhou R.J., Hui G.Z, Wu J.C., Huang G. Comparison of whole-body 18F-FDG SPECT and posttherapeutic 131I scintigraphy in the detection of metastatic thyroid cancer // Clin. Imaging. 2008. Vol. 32 (1). P. 32–37. doi: 10.1016/j.clinimag.2007.07.010Wang H., Fu H.L., Li J.N., Zhou R.J., Hui G.Z, Wu J.C., Huang G. Comparison of whole-body 18F-FDG SPECT and posttherapeutic 131I scintigraphy in the detection of metastatic thyroid cancer // Clin. Imaging. 2008. Vol. 32 (1). P. 32–37. doi: 10.1016/j.clinimag.2007.07.010.

The authors declare that there are no conflicts of interest present.